Document:

Exhibit 10.7

ROYALTY AND SUBLICENSE INCOME AGREEMENT 

This ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”),
dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”),
(ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan
limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).

WHEREAS, PureTech is required to provide certain funding, management
services and intellectual property as set forth in (i) the Note Purchase Agreement dated on or about the date hereof by and between Gelesis-US
and PureTech and (ii) the Management and Overhead Services Agreement dated on or about the date hereof by and between Gelesis-US and PureTech;

WHEREAS, PureTech will receive certain consideration for such funding,
management services and intellectual property, including the potential royalty payments and sublicense payments set forth herein;

NOW, THEREFORE, in consideration of the mutual promises hereinafter
set forth and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree
as follows:

1. Definitions. Reference is made to that certain Patent License
and Assignment Agreement dated December 9, 2009 (the “License Agreement”) by and among Gelesis-Bermuda, One S. R. L.,
Luigi Ambrosio, Luigi Nicolais and Alessandro Sannino. All capitalized terms not otherwise defined herein shall have the meanings ascribed
to them in the License Agreement.

2. Royalties.

(a) Gelesis shall pay to PureTech, during the applicable term described
in Section 2(b) below, earned royalties at the following rates:

	Type of Licensed Product	 	Rate	 
	A royalty on all Net Sales by Gelesis-Bermuda, its affiliates or any Sublicensee of Licensed Products that are not FoodProducts:	 	 	2	%
	A royalty on all Net Sales by Gelesis-Bermuda or its affiliates of Licensed Products that are Food Products:	 	 	2	%

If the manufacture, use, lease, or sale of any Licensed Product is
covered by more than one of the Valid Claims under the Patent Rights in the Field, or any patents in the Improvements or Food IP, multiple
royalties shall not be due.

(b) The Parties hereby agree that should intellectual property rights
owned by a third party pose as an obstacle to the development or commercialization of any Licensed Product that is not a Food Product
(the “Blocking IP”), Gelesis-Bermuda or an applicable affiliate of Gelesis-Bermuda shall, after consulting in good
faith with PureTech, seek a potential settlement solution with the Blocking IP holder and the royalty rates for Licensed Products that
are not Food Products set forth in Section 2(a) shall be reduced by the amount of such consideration paid for the rights to such Blocking
IP; provided, however that in no case shall the royalty rates for Licensed Products that are not Food Products set forth in Section 2(a)
be reduced by more than fifty percent (50%) as a result of the application of this Section 2(b).

(c) The obligation of Gelesis to pay royalties pursuant to Section
2(a) shall terminate on a country-by-country basis concurrently with (i) the expiration or termination of the applicable Valid Claim under
the Patent Rights in the country in which the Licensed Product is sold, or (ii) the withdrawal, cancellation, or disclaiming of the applicable
Valid Claim under the Patent Rights in the country in which the Licensed Product is sold.

     

     

    

3. Sublicense Income. Gelesis shall pay to PureTech ten percent
(10%) of Sublicense Income received by Gelesis and its affiliates on Food Products.

4. Reports and Payments. Following the
commencement of Gelesis’s obligations to pay any royalties pursuant to Section 2, Gelesis shall deliver to PureTech within sixty
(60) days after the end of each calendar quarter a written report showing its computation of royalties due under this Agreement for such
calendar quarter. Simultaneously with the delivery of each such report, Gelesis shall tender payment of all amounts shown to be due thereon.
The royalty payments due on sales in currencies other than U.S. dollars shall be calculated using the appropriate exchange rate for such
currency quoted by the relevant Government Authority as published by the Wall Street Journal on the last business day of the calendar
quarter to which such report relates. All amounts due under this Agreement shall be paid to PureTech in U.S. dollars by wire transfer
to an account in a bank designated by PureTech, or in such other form and/or manner as PureTech may reasonably request. During the term
of this Agreement, PureTech, at its cost, shall have the right from time to time (not to exceed once during each calendar year) to engage
a certified public accountant, reasonably acceptable to Gelesis, to inspect, during normal business hours, upon reasonable advance notice
(not less than one week), and subject to a written obligation of confidentiality acceptable to Gelesis, such books, records and other
supporting data of Gelesis as may be necessary to verify Gelesis’s computation of royalties due under this Agreement.

5. Withholding Taxes. All payments made by Gelesis to PureTech
shall be net of withholding taxes.

6. Miscellaneous.

(a) Transfers of Rights under this Agreement. This Agreement,
and the rights and obligations of each party hereunder, may not be assigned by any party without the prior written consent of each of
PureTech and Gelesis.

(b) Successors and Assigns. The provisions of this Agreement
shall inure to the benefit of, and be binding upon, the respective successors, permitted assigns, heirs, executors, and administrators
of the parties hereto and shall inure to the benefit of and be enforceable by each party hereto.

(c) Notices. Any notice, demand, request or delivery required
or permitted to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed given (i) when delivered personally
or when sent by facsimile transmission and confirmed by telephone or electronic transmission report (with a hard copy to follow by mail),
(ii) on the next business day after timely delivery to a generally recognized receipted overnight courier (such as FedEx) and (iii) on
the third business day after deposit in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid), addressed
to the party at such party’s address as set forth on the signature pages hereto or as subsequently modified by written notice delivered
as provided herein.

(d) Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware and the laws of the United States applicable therein (without giving effect to any
choice or conflict of laws provision or rule that would cause the application of the laws of any other jurisdiction) and shall be treated
in all respects as a Delaware contract.

(e) Waivers and Amendments. Except as otherwise expressly set
forth in this Agreement, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only by written agreement of PureTech, Gelesis-US and
Gelesis-Bermuda. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall
be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

(f) Delays or Omissions. No delay on the part of any party in
exercising any right, power, remedy or privilege hereunder shall operate as a waiver thereof nor shall any waiver on the part of any party
of any such right, power, remedy or privilege, nor any single or partial exercise of any such right, power, remedy or privilege, preclude
any further exercise thereof or the exercise of any other such right, power, remedy or privilege. All remedies, either under this Agreement,
by law, or otherwise afforded to the parties, shall be cumulative and not alternative.

     

     

    

(g) Titles and Subtitles. The titles
of the sections and subsections of this Agreement are for convenience of reference, only and are not to be considered in construing this
Agreement.

(h) Entire Agreement. This Agreement embodies the entire agreement
and understanding among the parties with respect to the subject matter hereof and related transactions, and supersedes all prior agreements
and understandings among the parties, written or oral, with respect thereto.

(i) Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

(j) Severability. If any provision of this Agreement shall be
held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and
shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall
be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.

(k) Non-Impairment. No amendment, waiver or termination of the
License Agreement following the date hereof shall have any effect on the terms of this Agreement unless such amendment, waiver or termination
is approved in writing by PureTech. In addition, each of Gelesis-US and Gelesis-Bermuda agree not to, through any reorganization, recapitalization,
reclassification, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid
or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by such party, but will at all
times in good faith assist in the carrying out of all the provisions of this Agreement and in the taking of all such action as may be
necessary or appropriate in order to protect the rights described herein against impairment.

[Remainder of Page Intentionally
Left Blank]

     

     

    

IN WITNESS WHEREOF, the parties have executed this Royalty and Sublicense
Income Agreement as of the date first above written.

	 	GELESIS, INC.
	 	 	 
	 	By:	/s/ Yishai Zohar
	 	Name:	 
	 	Title:	 
	 	Address:	
    222 Berkeley Street, Suite 1040

    Boston, Massachusetts 02116

    Fax: 617. 482. 2333

    

	 	 
	 	GELESIS, LP
	 	 	 
	 	By:	/s/ Yishai Zohar
	 	Name:	 
	 	Title:	 
	 	Address:	
    222 Berkeley Street, Suite 1040

    Boston, Massachusetts 02116

    Fax: 617. 482. 2333

     

	 	PURETECH VENTURES, LLC
	 	 	 
	 	By:	/s/ Daphne Zohar
	 	Name:	 
	 	Title:	 
	 	Address:	
    222 Berkeley Street, Suite 1040

    Boston, Massachusetts 02116

    Fax: 617. 482. 2333

    

     

     

    

 

AMENDMENT NO. 1 TO ROYALTY AND SUBLICENSE INCOME
AGREEMENT 

This Amendment No. 1 (“Amendment No. 1”) to the
Royalty and Sublicense Income Agreement dated as of December 18, 2009 (the “Agreement”) by and among Gelesis, Inc,
a Delaware corporation (“Gelesis-US”), Gelesis IP L. P., a Bermudan limited partnership (“Gelesis-Bermuda”),
and PureTech Ventures, LLC, a Delaware limited liability company (“PureTech”), is entered into on this 28th day of
June, 2012 by and among Gelesis-US, Gelesis-Bermuda, PureTech, and Gelesis, LLC, a Delaware limited liability company (“Gelesis.
LLC”). This Amendment No. 1 shall not become binding and shall have no effect unless and until Gelesis, Inc. enters into a License
and Collaboration Agreement (the “Gelesis/AZ Agreement”) with AstraZeneca AB (“AstraZeneca”) substantially
in the form attached hereto as Exhibit A. The date on which the Gelesis/AZ Agreement is signed shall be the effective date (the “Amendment
No. 1 Effective Date”) of this Amendment No. 1. For purposes hereof, all capitalized terms used herein but not defined herein
shall have the meanings given to them in the Master Agreement and License Agreement.

Pursuant to Section 6(e) of the Agreement and Section 9. 9 of the License
Agreement, Gelesis-US, Gelesis-Bermuda, Gelesis, LLC, and PureTech hereby agree as follows:

1. The parties hereby agree that Gelesis-US and Gelesis-Bermuda hereby
assign to Gelesis, LLC, and Gelesis, LLC hereby accepts and assumes, all rights, interests, and obligations under this Agreement. All
references to “Gelesis-US”, “Gelesis-Bemuda”, and “Gelesis” in the Agreement shall hereafter be deemed
to refer to Gelesis, LLC.

2. Section 2 of the License Agreement is hereby deleted and replaced
its their entirety as follows:

“2. In the event that, on a country-by-country basis, one or
more patents are issued by the patent authority in that country and contain a Valid Claim, Gelesis LLC shall pay to PureTech Ventures,
LLC two percent (2%) of Net Sales of such Licensed Product during the Calendar Year. For the avoidance of doubt there is no increase to
the royalty for more than one Valid Claim. In the event that, on a country-by country basis, there is no Valid Claim, Gelesis LLC shall
pay to PureTech five percent (5%) of any royalty paid to Gelesis, LLC by AstraZeneca pursuant to Section 10. 5. 2 (i. e. Royalty Scenario
2) of the Gelesis/AZ Agreement. The royalties referred to in Section 2 shall (i) be paid to PureTech within thirty (30) days following
receipt of such royalty by Gelesis, LLC from AstraZenca and (b) be subject to all of the same adjustments as the royalties payable to
Gelesis, LLC under the AstraZeneca Agreement.”

Solely for purposes of this Section 1 of this Amendment No. 1, all
capitalized terms shall have the meanings ascribed to them in the Gelesis/AZ Agreement.

3. In the event that the Gelesis/AZ Agreement is terminated, PureTech
may request in writing that the Amendments set forth in Section 2 of this Amendment No. 1 be terminated. In such event, the amendment
set forth in Section 2 of this Amendment No. 1 shall terminate and be of no further force or effect.

4. The Agreement (including Amendment No. 1) are hereby confirmed and
continue in all other respects.

[Remainder of Page Intentionally
Blank.]

     

     

    

IN WITNESS WHEREOF, the parties have caused this Amendment No to be
executed by their duly authorized representatives as of the Amendment No, 1 Effective Date.

	 	 	 
	GELESIS, INC.	 
	 	 	 
	By:	/s/ Yishai Zohar	 
	Name:	Yishai Zohar	 
	Title:	Chief Executive Officer	 
	 	 
	GELESIS LLC	 
	 	 	 
	By:	/s/ Yishai Zohar	 
	Name:	Yishai Zohar	 
	Title:	Chief Executive Officer	 
	 	 
	GELESIS IP L.P.	 
	 	 	 
	By:	/s/ Yishai Zohar	 
	Name:	 	 
	Title:	 	 
	 	 
	PURETECH VENTURES, LLC:	 
	 	 	 
	By:	/s/ Stephen Muniz	 
	Name:	Stephen Muniz	 
	Title:	PartnerExhibit 10.8

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT
MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.

 

SECOND AMENDED AND RESTATED

SUPPLY AND DISTRIBUTION AGREEMENT

 

This SECOND AMENDED
AND RESTATED SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”), is made and entered into as of the first day of
July, 2021 (the “Second Restatement Date”), by and between Roman Health Pharmacy LLC, a Delaware limited liability
company, having its principal office at 900 Broadway, Suite 706, New York, NY 10003 (“RO”) and Gelesis Inc., a Delaware
corporation, having its principal office at 501 Boylston Street, Suite 6102, Boston, MA 02116 (“GELESIS”). RO and GELESIS
each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

 

WITNESSETH:

 

WHEREAS,
GELESIS has developed and manufactured the medical device product PLENITYTM, an orally administered, non-stimulant, non-systemic
prescription aid in the form of capsules for weight management, as further described on Schedule A (the “Product”)
and has obtained a de novo classification order from the FDA (as defined below) to market, distribute and sell the Product in the United
States; and

 

WHEREAS,
GELESIS desires to appoint RO as the exclusive distributor of the Product in the Territory in the Field (each as defined below);

 

WHEREAS,
GELESIS further agrees to supply RO with the Product under the terms and conditions of this Agreement;

 

WHEREAS, RO
desires to serve as the exclusive distributor of the Product in the Territory in the Field and to purchase the Product from GELESIS, in
each case, subject to the terms and conditions of this Agreement;

 

WHEREAS, the
Parties previously entered into that certain Supply and Distribution Agreement, made and entered into as of the Effective Date (defined
below) (the “Original Agreement”)

 

WHEREAS, the
Parties amended and restated the Original Agreement pursuant to that certain Amended and Restated Supply and Distribution Agreement made
and entered into as of the Restatement Date (defined below) (the “First Amended and Restated Agreement”); and

 

WHEREAS, the
Parties now desire to amend and restate the First Amended and Restated Agreement in its entirety as follows;

 

NOW, THEREFORE,
in consideration of the foregoing premises and the mutual promises and covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

 

    1 

     

    

 

ARTICLE 1

DEFINITIONS

 

Unless otherwise
specifically provided herein, the following terms shall have the following meanings:

 

1.1.           
“Adverse Event” means an event involving a (i) death, or (ii) an injury or illness that is life-threatening,
results in irreversible impairment or damage to a body structure or function, or necessitates medical or surgical intervention to preclude
irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage, where the event was or may
have been attributed to the Product, or the Product was or may have been a factor in the event, including events occurring as a result
of user error, the manufacture, design or labeling of the Product, or the failure or malfunction of the Product.

 

1.2.            “Affiliate”
means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with such first Person at any time for so long as such Person controls, is controlled by
or is under common control with such first Person. For purposes of this definition, “control” and, with correlative
meanings, the terms “controlled by” and “under common control with,” shall mean (a) the possession, directly
or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by
contract relating to voting rights or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of more than
fifty percent (50%) of the voting securities or other ownership interest of a Person (or, with respect to a limited partnership or
other similar entity, its general partner or controlling entity); provided that, if local law restricts foreign ownership, control
will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by
foreign interests.

 

		1.3.	“Agreement” has the meaning set forth in the preamble.

 

		1.4.	“Allotment Confirmation” has the meaning set forth in Section 4.2(a).

 

1.5.            
“Allotment Period” [***].

 

1.6.           
“Applicable Law” means all foreign, federal, state and local laws, rules, regulations and requirements of governmental
and regulatory authorities applicable to the Parties, this Agreement, or the Manufacture, storage, handling, transportation, prescribing,
Distribution and use of the Product in the Territory.

 

		1.7.	“Audit” has the meaning set forth in Section 7.2(a).

 

		1.8.	“Breaching Party” has the meaning set forth in Section 13.2(a).

 

1.9.            
“Business Day” means a day that is not a Saturday, Sunday or day on which banking institutions in New York,
New York are required by law to remain closed.

 

    2 

     

    

 

1.10.        
 “CGMP” means the current good manufacturing practices and quality system requirements applicable to the Manufacturing,
handling, storage and distribution of the Product pursuant to Applicable Law, including, the regulations of the FDA in 21 C.F.R. Part
820, as from time to time in effect.

 

1.11.          
“Change of Control” means, with respect to a Person, any of the following transactions with a Third Party (a
 “Third Party Acquirer”): (a) a merger or consolidation of such Person with the Third Party Acquirer which results in
the holders of the voting securities of such Person outstanding immediately prior thereto (other than the Third Party Acquirer, its “affiliates”
and “associates” (as such terms are used in the Exchange Act)) ceasing to represent at least fifty percent (50%) of
the combined voting power of the surviving entity (or, if applicable, its parent company) immediately after such merger or consolidation;
(b) the sale to the Third Party Acquirer of all or substantially all of the business of such Person to which this Agreement relates (whether
by merger, consolidation, sale of stock, sale of assets or other similar transaction); or (c) the Third Party Acquirer (which shall not
be any trustee or other fiduciary holding securities under an employee benefit plan of such Person, or any corporation owned directly
or indirectly by the stockholders of such Person, in substantially the same proportion as their ownership of stock of such Person), together
with any of the Third Party Acquirer’s “affiliates” or “associates”, as such terms are used in the Exchange
Act, becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Person
or by contract or otherwise having the right to control the Board of Directors or equivalent governing body of such Person or the ability
to cause the direction of management of such Person.

 

1.12.         
“Company Names” means GELESIS’ (or its successor in interest’s) corporate name(s), as may be used
in connection with the Distribution of the Product in the Field in the Territory.

 

1.13.          
“Competing Product” [***].

 

		1.14.	“Complaining Party” has the meaning set forth in Section 13.2(a).

 

1.15.         
“Confidential Information” means, with respect to a Party, all confidential and proprietary information provided
by or on behalf of such Party to another Party either in connection with the discussions and negotiations pertaining to this Agreement
or in the course of performing this Agreement, whether or not marked as confidential, including without limitation know-how, knowledge,
practices, processes, ideas, research plans, engineering designs and drawings, research data, personal data, manufacturing processes and
techniques; scientific, manufacturing, marketing and business plans, and financial and personnel matters, sales, suppliers, customers,
employees, investors or business. For purposes of this Agreement, the terms of this Agreement shall be deemed to be Confidential Information
of both Parties.

 

1.16.         
“Contract Manufacturer” means any Third Party contract manufacturer of GELESIS to Manufacture the Product to
be supplied to RO under this Agreement, which are listed on Schedule B, as amended from time to time.

 

		1.17.	“Court” has the meaning set forth in Section 14.7.

 

1.18.           “Default
Shipping Costs” means the actual, out-of-pocket costs incurred by RO or any of its Affiliates for the shipping option for
each package of the Product shipped, which shipping option shall be selected by GELESIS from RO’s standard shipping options
from time to time on its or its Affiliates’ telehealth platform. Such shipping costs will not be charged to the End Users
selecting such standard shipment option.

 

    3 

     

    

 

		1.19.	“Disclosing Party” has the meaning set forth in Section 11.1.

 

1.20.          
 “Distribute” means sell, have sold, provide, have provided, ship, have shipped, distribute, have distributed,
and otherwise commercialize and have commercialized.

 

		1.21.	“Effective Date” means August 26, 2019.

 

1.22.          
“End User” means any patient for whom the Product has been indicated for use per the de novo classification
order issued by the FDA.

 

1.23.           
“Exclusive Period” [***].

 

1.24.           
“FDA” means the United States Food and Drug Administration and any successor agency thereto.

 

1.25.           
“Field” [***].

 

1.26.           
“First Amended and Restated Agreement” has the meaning set forth in the recitals.

 

		1.27.	“Force Majeure” has the meaning set forth in Section 14.1.

 

		1.28.	“GELESIS” has the meaning set forth in the preamble.

 

		1.29.	“GELESIS Indemnified Parties” has the meaning set forth in Section

12.2.

		1.30.	“GELESIS Intellectual Property” has the meaning set forth in Section

9.1.

		1.31.	“Health Care Provider” means doctors, registered nurses, advanced practice registered nurses, and physician’s assistants.

 

		1.32.	“ICC” has the meaning set forth in Section 14.6(a).

 

1.33.          
“Indemnified Party” means the Party seeking indemnification for Losses pursuant to Section 12.1 or 12.2.

 

1.34.           
“Indemnifying Party” means the Party from which indemnification is sought pursuant to Section 12.1 or 12.2.

 

1.35.           
“Initial 2021 Purchase” has the meaning set forth in Section 4.2(g).

 

1.36.           
“Lookback Period” means, with respect to each Allotment Confirmation, [***].

 

    4 

     

    

 

		1.37.	“Losses” has the meaning set forth in Section 12.1.

 

1.38.          
“Mail Order/Online Pharmacy” means the business of (a) receiving orders for medical products or devices that
are submitted by or on behalf of End Users or Health Care Providers via postal or other package delivery services, or via telecommunications,
internet, or other remote communication technologies, and (b) filling such orders by shipping such products or devices to such End Users.

 

1.39.         
“Manufacture” and “Manufacturing” means, with respect to the Product, the manufacturing,
processing, formulating, packaging, labeling, holding and quality control testing of the Product.

 

1.40.         
“Named Competitors” means the following Third Parties (and their successors or assigns of their respective business
in the Field) and each of their respective Affiliates: [***].

 

		1.41.	“Notice Period” has the meaning set forth in Section 13.2(a).

 

		1.42.	“Original Agreement” has the meaning set forth in the recitals.

 

		1.43.	“Party” and “Parties” have the meanings set forth in the preamble.

 

		1.44.	“Payee” has the meaning set forth in Section 6.5(c).

 

1.45.         
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other
similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.46.          
“Previous Supply Price” means [***] for each twenty eight (28)-day supply unit of the Product purchased by RO,
which supply price was in effect prior to the Restatement Date.

 

		1.47.	“Product” has the meaning set forth in the recitals.

 

1.48.         
“Product Packaging” means (a) any container, packaging, or wrapper of a Product and all labels and other written,
printed or graphic matter affixed to any container, packaging or wrapper utilized with a Product, (b) any written material packaged with
or otherwise physically accompanying a Product, including package inserts, and (c) any written material related to (a) or (b) that is
required to be submitted to or approved by a Regulatory Authority or that is subject to Applicable Law.

 

1.49.          
“Product Quality Complaint” means such Manufacturing or packaging- related complaints or other complaints alleging
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance received from Third Parties
related to a Product, including complaints involving the possible failure of a Product to meet any of the Specifications.

 

    5 

     

    

 

1.50.          
 “Product Trademark” means the Trademark PLENITYTM, all packaging designs and other trade dress used in
connection with the Product and such other Trademarks relating thereto and any registrations thereof or any pending applications relating
thereto.

 

		1.51.	“Public Announcement” has the meaning set forth in Section 11.7.

 

		1.52.	“Purchase Order” has the meaning set forth in Section 4.2(b).

 

1.53.         
“Reasonable Efforts” means, with respect to an activity to be conducted by a Party, the level of effort that
would generally be used by a similarly situated company to conduct such activity with respect to a product owned by it or to which it
has rights similar to the rights contemplated under this Agreement, at a similar stage in its development or product life, taking into
account, without limitation, issues of safety and efficacy, product profile, the proprietary position, the then-current competitive environment
for such product, the likely timing of the product’s entry into the market, the regulatory environment and status of the product,
and other relevant scientific and technical factors, in each case as measured by the facts and circumstances at the time such efforts
are due.

 

		1.54.	“Receiving Party” has the meaning set forth in Section 11.1.

 

1.55.         
“Regulatory Approval” means any and all approvals, clearances, orders, licenses, registrations or authorizations
of the FDA, or other federal, state or local regulatory authorities, necessary for the sale and marketing of the Product in the Field
in the Territory, including a de novo classification order for the Product, Manufacturing approval or authorization and labeling
approval or labeling in accordance with Applicable Law related thereto.

 

1.56.         
“Regulatory Authorities” means any applicable supra-national, federal, national, regional, state, provincial
or local regulatory agencies, departments, bureaus, commissions, councils or other government entities, including the FDA and any entity
exercising regulatory authority with respect to the Manufacture, Distribution, use, or other regulation of the Product in the Territory.

 

1.57.         
“Regulatory Documentation” means all applications, submissions, registrations, licenses, authorizations and
approvals (including all Regulatory Approvals) and all correspondence submitted to or received from the FDA or other federal, state or
local regulatory authorities (including minutes and official contact reports relating to any communications with the FDA or other federal,
state or local regulatory authorities) and all supporting documents and all clinical studies and tests, relating to a Product and all
data contained in any of the foregoing or required to be maintained pursuant to Applicable Law, including advertising and promotion documents,
Adverse Event files, Product Quality Complaint files and Manufacturing records.

 

1.58.          
“Restatement Date” means January 12, 2021.

 

		1.59.	“RO” has the meaning set forth in the preamble.

 

		1.60.	“RO Indemnified Parties” has the meaning set forth in Section 12.1.

 

		1.61.	“RO Sales Amount” has the meaning set forth in Section 4.3.

 

    6 

     

    

 

		1.62.	“Sales Tax” has the meaning set forth in Section 6.6.

 

		1.63.	“Second 2021 Purchase” has the meaning set forth in Section 4.2(g).

 

1.64.          
“Second Restatement Date” has the meaning set forth in the preamble.

 

1.65.          
“Specifications” means the specifications and quality control testing procedures, including the requirements
set forth in the Regulatory Approvals, for a Product, each as may be amended or supplemented from time to time by GELESIS in accordance
with Section 8.5.

 

		1.66.	“Supply Payment” has the meaning set forth in Section 6.2(a).

 

1.67.          
“Supply Price” means, for each twenty eight (28)-day supply unit of the Product purchased by RO, (i) [***] for
the Initial 2021 Purchase, (ii) [***] for the Second 2021 Purchase, and (iii) thereafter, the price that is mutually agreed by the Parties
in writing (which price shall be no more than [***] for each twenty eight (28)-day supply unit of the Product purchased by RO).

 

		1.68.	“Term” has the meaning set forth in Section 13.1.

 

1.69.          
“Territory” [***].

 

1.70.          
“Third Party” means any Person other than GELESIS and RO, or their respective Affiliates.

 

		1.71.	“Third Party Acquirer” has the meaning set forth in Section 1.11.

 

1.72.          
“Trademark” shall include any word, name, symbol, color, designation or device or any combination thereof, including
any trademark, trade dress, brand mark, trade name, brand name, logo or business symbol together with the goodwill of the business associated
therewith and symbolized thereby.

ARTICLE 2

RIGHT OF DISTRIBUTION; EXCLUSIVITY

 

2.1.            
Exclusive Distributorship. During the Exclusive Period, GELESIS hereby appoints RO and its Affiliates as the exclusive distributor
of the Product in the Field in the Territory, and grants RO and its Affiliates the exclusive right to Distribute the Product in the Field
in the Territory.

 

2.2.            
Exclusive License. Subject to Section 9.2, during the Exclusive Period, GELESIS hereby grants to RO and its Affiliates an
exclusive (except as set forth expressly in Section 2.3(b)), royalty-free, fully paid up license, with the right to transfer or sublicense
solely in accordance Section 14.4, under Gelesis’ right, title and interest in and to Product Trademarks and Company Names, to use
the Product Trademarks and Company Names in accordance with the terms of this Agreement solely for the purposes of Distribution of the
Product in the Field in the Territory.

 

    7 

     

    

 

		2.3.	Exclusivity.

 

                (a)            During
the Exclusive Period, [***].

 

                (b)           During
the Exclusive Period, [***].

 

2.4.           
Extension of Exclusive Period. The Exclusive Period may be extended by mutual written agreement of the Parties. On or before
the date that is ninety (90) days prior to the end of the initial Exclusive Period (and any extension thereof), each Party will inform
the other Party of its intention to either extend the Exclusive Period or to permit the Exclusive Period to expire.

 

2.5.           
Expiration of the Exclusive Period. Unless otherwise agreed by the Parties in writing, upon expiration of the Exclusive
Period, the exclusive right and license granted by GELESIS to RO and its Affiliates under Section 2.1 and Section 2.2 shall automatically
convert to non-exclusive for the remainder of the Term.

 

ARTICLE 3

 COMMERCIALIZATION
OF THE PRODUCT

 

3.1.           
Distribution Efforts. During the Term, RO shall use Reasonable Efforts to Distribute the Product in the Field in the Territory.
Subject to GELESIS meeting its obligations pursuant to ARTICLE 4, RO shall maintain an inventory of Product and a distribution network
that are sufficient to permit reasonably prompt delivery of Product to customers and to meet reasonably anticipated market demand for
the Product in the Field in the Territory.

 

3.2.           
Packaging and Labeling. GELESIS shall be responsible, at its sole expense, for providing all Product Packaging for the Product
to be Distributed in the Territory in the Field under this Agreement in accordance with all Regulatory Approvals and Applicable Law. Any
changes to the labeling and packaging of the Product in the Territory shall be subject to Section 8.5.

 

3.3.            
Expired Product. RO may not sell the Product with an expired shelf life, and RO shall dispose of such expired Product at
RO’s expense in accordance with Gelesis’ written instructions and Applicable Law.

 

ARTICLE 4

SUPPLY OF PRODUCT

 

4.1.            General. Subject to the terms and conditions of this Agreement, during the Term, GELESIS agrees to supply RO with, and RO
agrees to purchase from GELESIS, all of RO’s requirements of supplies of the Product in finished, packaged form subject to Sections
4.2 and 4.3.

 

		4.2.	Supply Amounts and Adjustment.

 

                   (a)   
RO will notify GELESIS at least 45 days prior to the anticipated date of first sale of the Product by RO or any of its Affiliates.
[***].

 

    8 

     

    

 

(b)             
 Within three (3) Business Days of receiving each Allotment Confirmation, RO shall submit to GELESIS a purchase order (“Purchase
Order”), which may be submitted via email, specifying (i) the amount of Product RO will order for each month during the Allotment
Period, which amount shall not exceed the maximum amount set forth in the Allotment Confirmation for each such month, and (ii) the delivery
date(s) for each month of supply, which date(s) shall be no earlier than seven (7) days prior to the beginning of such month. For the
avoidance of doubt, RO may specify multiple delivery dates (at intervals no shorter than weekly) for any and all months covered by the
applicable Purchase Order.

 

                 (c)   
[***].

 

                
(d)    [***].

 

(e)             
If Product is delivered to RO with less than five (5) months of shelf life remaining and RO fails to sell or dispense such Product
during the applicable Lookback Period before it expires, then, for purposes of the calculations set forth in Sections 4.2(c) and 4.2(d),
such Product shall not count as Product delivered by GELESIS to RO for such Lookback Period.

 

(f)              
Notwithstanding Sections 4.2(c) and 4.2(d), GELESIS may increase the maximum amount of the Product to be supplied in any Allotment
Confirmation at its own discretion.

 

(g)               Notwithstanding
the foregoing or anything to the contrary herein, the Parties acknowledge and agree that (i) RO’s initial purchase made during
the 2021 calendar year was [***] 28-day supply units (the “Initial 2021 Purchase”) and (ii) RO’s second
purchase made during the 2021 calendar year will be [***] 28-day supply units (the “Second 2021 Purchase”). The
Initial 2021 Purchase and the Second 2021 Purchase will be delivered by GELESIS pursuant to the delivery schedule provided by RO in
Purchase Orders submitted by RO from time-to-time on an as needed basis, subject to the following minimums. With respect to the
Initial 2021 Purchase, at least [***] 28-day supply units of Product will be shipped by January 15, 2020, and at least [***]
additional 28-day supply units of Product will be delivered on the first day of each month in 2021 thereafter until the entire
Initial 2021 Purchase has been fulfilled, in each case to the delivery location(s) designated by RO in the applicable Purchase
Order; provided that GELESIS shall deliver at least [***] of the Initial 2021 Purchase (i.e., [***] 28-day supply units of
Product) by November 30, 2021 to the delivery location(s) designated by RO in the applicable Purchase Orders. With respect to the
Second 2021 Purchase, at least [***] 28-day supply units of Product will be delivered by September 1, 2021, at least [***]
additional 28-day supply units of Product will be delivered by the first day of each of October 2021, November 2021, and December
2021, and at least [***] additional 28-day supply units of Product will be delivered on the first day of each month in 2022
thereafter until the entire Second 2021 Purchase has been fulfilled, in each case to the delivery location(s) designated by RO in
the applicable Purchase Order. Upon notice from RO to GELESIS that RO is nearing depletion of the Second 2021 Purchase, GELESIS
shall provide RO with an Allotment Confirmation for the following Allotment Period, and Sections 4.2(a)-(f) shall continue to
apply.

 

    9 

     

    

 

4.3.             Supply
Shortage. In the event of any shortage experienced by GELESIS with respect to any inputs or capacity that may reasonably be
expected to affect GELESIS’ ability to satisfy its supply obligations hereunder in respect of a particular month, then GELESIS
shall notify RO promptly after it becomes aware of such circumstances that could reasonably be expected to result in any such
shortage. GELESIS shall, unless mutually agreed otherwise by the Parties, allocate its available inputs and capacity pro rata
amongst the affected Purchase Order(s) and any order of any Third Party dispensing the Product that has been prescribed by a Health
Care Provider to an End User in the course of providing medical services to such End User in person. [***].

 

4.4.              Delivery. Subject to Section 4.3, GELESIS shall deliver all quantities of the Product set forth in each Purchase Order DDP
(incoterms 2010) to up to [***] delivery locations within the Territory as may be specified from time to time by RO, at GELESIS’
sole cost and expense, on the dates specified in such Purchase Order. Title and risk of loss and damage to the Product shall pass to RO
upon delivery of the Product to RO at the delivery location(s) specified in the applicable Purchase Order. For the avoidance of doubt,
GELESIS shall be solely responsible for importation of the Product into the Territory and any costs and expenses associated therewith.
If GELESIS does not satisfy its delivery requirements for a particular month by the date that is ten (10) days following the delivery
date set forth in the applicable Purchase Order, GELESIS shall, at RO’s sole discretion, (a) refund the amount paid by RO or its
Affiliates for the undelivered Product (or any portion thereof), or (b) deliver such ordered Product as soon as reasonably possible, but
in no event no later than thirty (30) days following the original delivery date set forth on the applicable Purchase Order.

 

4.5.             Initial Inspection. Upon delivery in accordance with Section 4.4, RO will have seven (7) Business Days to inspect each delivery
of the Product, and shall report any defects in quantity or nonconformance with the Product warranty set forth in Section 5.1 identifiable
from visible inspection to GELESIS within such period. If no such report is received by GELESIS within such period, RO will be deemed
to have accepted such Product. If such report is timely provided by RO, then:

 

                   (a)   
If GELESIS does not agree with RO on the alleged nonconformance in the report, a designee of RO and a designee of GELESIS shall
promptly meet to discuss and attempt to resolve the dispute in good faith within five (5) Business Days. If the Parties cannot resolve
the dispute within five (5) Business Days, the Parties shall designate an independent testing laboratory reasonably acceptable to both
Parties for a determination, which determination shall be binding on the Parties, absent manifest error. If the Parties cannot agree on
an independent testing laboratory within ten (10) Business Days, then either Party may, upon notice to the other Party, refer the dispute
to arbitration in accordance with Section 14.6(a). The Parties shall attempt to resolve any such dispute within ninety (90) days.

 

                   (b)   
If GELESIS agrees with RO that the Product identified in the report is nonconforming, or, pursuant to Section 4.5(a), it is ultimately
determined that the Product identified in the report is nonconforming, then as GELESIS’ sole liability and RO’s sole remedy
with respect to such nonconforming Product, GELESIS shall deliver replacement Product at no additional charge to RO in substitution for
the nonconforming Product.

 

    10 

     

    

 

ARTICLE 5

PRODUCT WARRANTY; QUALITY

 

5.1.           
 Product Warranty. GELESIS hereby represents and warrants that any Product delivered to RO hereunder will (a) be free from
any defects; (b) be designed, manufactured, packaged, labeled, stored, and distributed in accordance with CGMP and Applicable Law; and
(c) conform to the Specifications and the applicable certificate of analysis at the time of delivery. GELESIS shall ensure that any Product
delivered to RO hereunder shall have at least [***], and in any event no less than [***], of its shelf life remaining at the time of delivery.
The Parties shall negotiate at quarterly intervals, on a good faith basis and taking into account the volume of Product sold by RO to
End Users in eighty four (84)-day supply units, to establish an amount of Product delivered to RO that shall have a shelf life of at least
[***]remaining at the time of delivery. In the event that Product is delivered to RO with less than [***] of shelf life remaining
at the time of delivery, the Parties will work together in good faith to increase the frequency that Product is shipped and delivered
to RO.

 

5.2.            
Intentionally Omitted.

 

5.3.            
Record Keeping by GELESIS. During the Term, GELESIS shall maintain, or cause to be maintained, all records necessary to
comply with all Applicable Law relating to the Manufacture and supply of the Product. All such records shall be maintained for such period
as may be required by Applicable Law; provided, however, that all records relating to the Manufacture, stability and quality control of
each batch of a Product shall be retained at least until the first (1st) anniversary of the end of the approved shelf life for all Product
from such batch.

 

		5.4.	Nonconforming Product.

 

                   (a)   
RO shall notify GELESIS in writing of any claim that any such Product supplied under this Agreement does not conform to the warranty
set forth in Section 5.1, which nonconformance was not identifiable upon visual inspection as provided in Section 4.5, within ten (10)
Business Days after RO becomes aware of any such nonconformity. RO shall provide GELESIS with a sample of such nonconforming Product,
if available, and all relevant reports, data, and laboratory test results. Failure by RO to provide notice of nonconformance within the
applicable timeframe shall constitute irrevocable acceptance of the Product by RO.

 

                   (b)   
If RO notifies GELESIS of any nonconforming Product pursuant to Section 5.4(a) (other than a claim that the Product does not conform
to Section 5.1(b)) and RO and GELESIS cannot agree as to whether such Product is nonconforming, RO and GELESIS shall designate an independent
testing laboratory reasonably acceptable to both Parties for a determination, which determination shall be binding on the Parties, absent
manifest error. The Party that was incorrect as to whether the Product was conforming shall pay the testing laboratory’s fees. If
the Parties cannot agree on an independent testing laboratory within ten (10) Business Days, or if the dispute relates to a claim that
the Product does not conform to Section 5.1(b), then either Party may, upon notice to the other Party, refer the dispute to arbitration
in accordance with Section 14.6(a). The Parties shall attempt to resolve any non-conformance issue within ninety (90) days.

 

                    (c)    If
GELESIS agrees that the Product identified by RO is nonconforming Product, or, pursuant to Section 5.4(b) it is ultimately
determined that the Product identified by RO is nonconforming, then as GELESIS’ sole liability and RO’s sole remedy with
respect to such nonconforming Product (except, in each case, with respect to any indemnification obligations arising pursuant to
Article 12), GELESIS shall, at RO’s option, either: (i) deliver replacement Products at no additional charge to RO in
substitution for the nonconforming Product, or (ii) refund to RO the price paid to GELESIS by RO for such nonconforming Product, or,
if the invoice has not been paid, cancel the invoice, and reimburse RO the costs for removal or disposal of such nonconforming
Product.

 

    11 

     

    

 

                    (d)   
If nonconforming Product is dispensed prior to the discovery of the nonconformance, RO or its Affiliates may notify Health Care
Providers and pharmacies associated with RO’s telehealth platform who prescribed or Distributed the nonconforming Product and End
Users to whom the nonconforming Product was dispensed of the nonconformance with a copy to GELESIS, if, in RO’s discretion, such
notice is reasonably appropriate to safeguard patient health and safety. Notwithstanding this section, any recall of the Product
will be conducted in accordance with Section 8.3.

 

ARTICLE 6

 PRICE AND
PAYMENT

 

		6.1.	Intentionally Omitted.

 

6.2.           
Payment by RO.

 

(a)             
Subject to Section 6.3, with respect to the Product purchased or delivered to a Ro facility as of the Restatement Date and sold
by RO or any of its Affiliates to any End User for a given month, RO shall pay to GELESIS:

 

(i)       [***]

 

(ii)       [***]

 

(A)       [***]

 

(B)       [***]

 

(C)       [***]

 

(D)       [***].

 

(b)       [***].

 

(c)       [***].

 

(d)       [***].

 

(e)       [***].

 

    12 

     

    

 

 

 

6.3.            Purchase
Price Adjustment. During the Term, if GELESIS enters into an arrangement with a Third Party with respect to Distribution or
commercial supply of the Product, whereby GELESIS provides such Third Party pricing (including volume discount pricing) for each
twenty eight (28)-day supply unit of the Product that is, taken as a whole, lower than the Previous Supply Price or the Supply
Price, as applicable, GELESIS shall promptly notify RO, and such lower pricing shall automatically apply to the Previous Supply
Price or the Supply Price, as applicable, of the Product supplied by GELESIS to RO hereunder effective as of the date such lower
pricing was made available to such Third Party, and, to the extent that RO has paid any amount for the Product in excess of such
adjusted price following the date such lower pricing was made available to such Third Party, GELESIS shall issue RO a credit equal
to such amount against future payment for the Product payable by RO (or, if there is a supply shortage at the time the credit would
be issued by GELESIS or used by RO, at RO’s option, GELESIS will issue RO a cash reimbursement or a credit).

 

6.4.           
Intentionally Omitted. 

 

6.5.           
Payment Terms.

 

(a)   
All payments payable by RO to GELESIS pursuant to Section 6.2(a) for a given month shall be paid in full by RO within thirty (30)
days following the end of such month. When making such payments, RO shall furnish to GELESIS a written report stating the number of packages
of the Product shipped, and the aggregate number of twenty eight (28)-day supply unit of the Product sold, in each case, by RO or any
of its Affiliates to End Users during such month, and the calculation of payments payable by RO to GELESIS pursuant to Section 6.2(a).
All payments payable by RO to GELESIS pursuant to Section 6.2(a) and 6.2(b)(i) have been timely paid in full by RO. The payment payable
by RO to GELESIS pursuant to Section 6.2(b)(ii) shall be due and payable by RO within thirty (30) days following the Second Restatement
Date and RO’s receipt of a correct invoice. All payments payable by RO to GELESIS pursuant to Section 6.2(c) for Product purchased
by RO during any calendar month shall be paid in full by RO within thirty (30) days of the end of such calendar month following receipt,
inspection and acceptance of a full and complete delivery of the applicable Products (including an invoice therefor). Any payments payable
by RO to GELESIS pursuant to Section 6.2(d) shall be paid in full by RO within thirty (30) days of the end of each calendar quarter for
Product sold during such calendar quarter having a resale price greater than [***] per twenty eight (28)-day supply unit, subject to any
refunds or returns as provided pursuant to Section 6.2(d).

 

(b)   
If there is any dispute with regard to the amount payable by RO to GELESIS pursuant to Section 6.2, RO shall not be obligated to
pay such disputed portion until the dispute is resolved by the Parties. The Parties shall use good faith efforts to resolve any such disputes
promptly. Upon resolution of any such dispute, RO shall pay to GELESIS the amounts determined to be due within five (5) Business Days.

 

(c)   
All payments to be made by one Party to the other Party (“Payee”) under this Agreement shall be made in United
States dollars and shall be paid by bank wire transfer or by automated clearinghouse (electronic funds transfer) in immediately available
funds to such bank account designated in writing by the Payee from time to time.

 

    13 

     

    

 

6.6.            Taxes.
The fees specified in this Agreement are exclusive of any sales, use, excise, or similar taxes (“Sales Tax”). RO
shall calculate and pay to GELESIS all Sales Tax imposed by any federal, state, provincial, local, or other governmental entity for
the Product or services provided under this Agreement, excluding, for the avoidance of doubt, any customs, duties, levies,
tariffs or similar charges of any kind, or any taxes based solely on GELESIS’ net income. In the event that GELESIS is
required to pay any such Sales Taxes, RO shall reimburse GELESIS for payment of such taxes paid. GELESIS agrees to cooperate in good
faith with RO to enable RO to secure any exemption from Sales Tax upon resale of the Product to End Users.

 

ARTICLE 7

INSPECTION
AND AUDIT

 

		7.1.	Inspections By RO.

 

(a)   
Annual Inspection. During the Term, and no more than once during any twelve (12) month period, upon at least thirty (30)
days prior written request of RO, RO and its designated agents may visit and conduct inspection of those portions of the facilities of
GELESIS, an Affiliate, or a Contract Manufacturer where the Product to be supplied under this Agreement is being Manufactured, during
regular business hours, to ascertain compliance with CGMP, Applicable Law, and the Specifications in the Manufacture, handling, storage,
and shipping of the Product, and to verify GELESIS’ compliance with the terms and conditions of this Agreement (an “Inspection”).
As part of any Inspection, RO and its agents may inspect (i) the materials used in the Manufacture of the Product, (ii) the holding facilities
for such materials, (iii) the equipment used in the Manufacture of the Product, and (iv) any related records.

 

(b)   
For Cause Inspection. In addition, RO may conduct an Inspection at any time upon reasonable prior notice to GELESIS if such
an Inspection is a reasonable response to a Regulatory Authority inquiry regarding any Product, a deviation in Manufacture of the Product,
Product Quality Complaint or Adverse Events regarding the Product, or a material breach of this Agreement.

 

(c)   
Regulatory Inspections. During the term of this Agreement, GELESIS shall notify RO promptly after learning of any proposed
or unannounced visit or inspection by any Regulatory Authority of any facility (whether owned by GELESIS, an Affiliate, or a Contract
Manufacturer) involved in the Manufacture or storage of the Product to be supplied under this Agreement. Unless the Regulatory Authority
objects or otherwise prohibited by Applicable Law, GELESIS shall permit RO or its agents to be present in such visit or inspection. GELESIS
shall provide to RO (i) a copy of any report or other written communications received by GELESIS from such Regulatory Authority in connection
with such visit or inspection within seven (7) days after receipt thereof, and (ii) a copy of all responses thereto submitted to such
Regulatory Authority as soon as practicable relating to the manufacture of the Product.

 

(d)   
Conditions on Inspections. RO shall bear all of its own costs related to any such Inspection or visit. During each Inspection,
RO and its designated agents may only inspect materials, facilities and equipment to the extent used in the Manufacture and supply of
the Product. Inspections may not unreasonably interfere with GELESIS’ operations or the operations of any of its Affiliates or Contract
Manufacturers. In addition, GELESIS may impose reasonable rules and requirements on an Inspection with respect to the protection of confidential
information or trade secrets by asking RO or its agents to execute a confidentiality agreement containing terms no less strict than the
relevant terms contained herein.

 

    14 

     

    

 

(e)    Remedial
Efforts. Following an Inspection, the Parties shall meet to discuss findings, and GELESIS shall use Reasonable Efforts to
implement (or cause any applicable Affiliate or Contract Manufacturer to implement) reasonable corrective action within sixty (60)
days of notification of any problems (or, if such implementation cannot reasonably be completed within sixty (60) days, GELESIS
shall commence such implementation or cause the Affiliate or Contract Manufacturer to commence such implementation, within sixty
(60) days, and shall diligently continue or shall have diligently continued such implementation thereafter).

 

7.2.           
Audit by GELESIS.

 

(a)   
Annual Audit. During the Term, at the request of GELESIS, RO shall permit GELESIS, through an independent accounting firm
retained by GELESIS at its sole cost, at reasonable times and upon reasonable prior written notice, to examine and audit the books and
records maintained by RO solely for purposes of verifying RO’s compliance with the terms and conditions of this Agreement, including
verifying RO’s compliance with its payment obligations pursuant to Section 6.2 (each, an “Audit”). RO and its
accountants shall cooperate with and permit such firm to review all invoices, receipts, and other appropriate information relating to
the Distribution of the Product.

 

(b)   
For Cause Audit Right. In addition, GELESIS may conduct an Audit at any time upon reasonable prior notice to RO if such
an Audit is a reasonable response to a material breach of this Agreement.

 

(c)   
Conditions on Audit. Any data related to patient personal information must be de-identified before such data can be audited.
Such examination and audit may not be conducted more than once in any twelve (12)-month period. Audits may not unreasonably interfere
with the RO’s operations or the operations of any of its Affiliates. In addition, RO may impose reasonable rules and requirements
on an Audit with respect to the protection of confidential information or trade secrets by asking the independent firm to execute a confidentiality
agreement containing terms no less strict than the relevant terms contained herein.

 

(d)   
Audit Results. RO shall receive a copy of the audit report furnished by such accounting firm to GELESIS. Should such Audit
lead to the discovery of a discrepancy of payments by RO to GELESIS’ detriment, and only to the extent that RO agrees with and accepts
such conclusion under the Audit, RO shall pay, within thirty (30) days after its receipt from the accounting firm of the audit report,
the amount of the discrepancy. If RO does not agree with the conclusion of such report, the matter shall be referred to arbitration in
accordance with Section

14.6. Should such Audit lead to
the discovery that an excess amount of payment has been made by RO to GELESIS, then GELESIS shall, within thirty (30) days after its receipt
from the accounting firm of the audit report, credit RO for such amount against its future payment obligations pursuant to Section 6.2
(or, if there is a supply shortage at the time the credit would be issued by GELESIS or used by RO, at RO’s option, GELESIS will
issue RO a cash reimbursement instead of a credit).

ARTICLE 8

REGULATORY MATTERS

 

		8.1.	Regulatory Documentation and Approvals; Communications.

 

(a)    During
the Term, GELESIS shall be responsible for preparing and filing all Regulatory Documentation necessary to obtain and maintain
Regulatory Approvals for the Product in the Territory; provided that RO shall have the primary responsibility to obtain and maintain
Regulatory Approvals to the extent solely related to RO’s Distribution of the Product in the Field in the Territory.

 

    15 

     

    

 

(b)   
Each Party shall have the right to communicate with Regulatory Authorities with respect to the Product (i) to the extent reasonably
necessary to exercise its rights, and perform its obligations hereunder, including under this Section 8.1, and (ii) to the extent required
by Applicable Law. Each Party shall keep the other Party informed of any material communication with Regulatory Authorities with respect
to the Product, and shall, in response to written requests from the other Party, provide the other Party a copy of any such material communications
with Regulatory Authorities, and any relevant Regulatory Documentation submitted to or received from the Regulatory Authorities with respect
to the Product.

 

(c)   
Each Party shall, upon reasonable request of, and at the cost of the other Party, cooperate with the other Party and assist the
other Party in connection with (i) preparing and filing of any Regulatory Documentation in connection with obtaining and maintaining Regulatory
Approvals for the Product in the Territory, and (ii) preparing for and conducting any material communications with applicable Regulatory
Authorities, in each case, as set forth in this Section 8.1.

 

8.2.           
Adverse Event, and Product Quality Complaint Notification and Reporting.

 

(a)     Each Party shall notify the other
Party promptly (and in no event later than two (2) Business Days of becoming aware of) any material communications from any
Regulatory Authority alleging any non-compliance with Applicable Laws or raising any concern, in each case, with respect to the
Manufacturing, quality, safety, efficacy or marketing of the Product (including any Form FDA 483 with inspectional observations,
Warning Letter, or Untitled Letter).

 

(b)   
GELESIS shall be solely responsible for submitting medical device reports, including for Adverse Events and applicable Product
Quality Complaints, with respect to a Product to FDA and comparable reports to applicable Regulatory Authorities, in conformance with
Applicable Law; provided, however, that each Party shall have the right to make such other reports or communications with applicable Regulatory
Authorities as are necessary to comply with Applicable Laws. RO or its Affiliate shall forward reports of Adverse Events to GELESIS no
later than two (2) business days of RO or its Affiliate’s becoming aware of such Adverse Event. RO or its Affiliate shall forward
reports of Product Quality Complaints of which RO or its Affiliate has become aware to GELESIS on a weekly basis in the form of a report
that removes identifying information for the complainants. GELESIS shall provide prompt notice to RO of any significant safety
issues or any other information that might necessitate a change in Product Packaging.

 

		8.3.	Product Recall and Market Withdrawal.

 

(a)    In
the event that any Regulatory Authority issues or requests a recall or market withdrawal or takes similar action in connection with
any Product in the Territory, GELESIS shall notify RO within one (1) business day of such issuance or request. In the event that
either Party determines that such a recall or market withdrawal of the Product may be necessary or advisable, such Party shall
advise the other Party thereof within one (1) business day of such determination. GELESIS shall also notify RO promptly in the event
of (i) the issuance of an FDA alert or similar alert or foreign equivalent thereof with respect to the Product, and (ii) any
communication from any Regulatory Authority regarding a potential recall or market withdrawal of any Product.

 

    16 

     

    

 

(b)   
Within a period of time reasonable under the circumstances after the date of a notice given pursuant to the first two sentences
of Section 8.3(a), GELESIS shall determine (i) whether to conduct a recall with respect to the Product in the Territory, (ii) the breadth
and extent of any such recall, (iii) the strategies and notifications to be used, and (iv) other related issues; provided, however, that,
notwithstanding anything contained in clause (i) of this Section 8.3(b), GELESIS shall be required to conduct such recall with respect
to the Product in the event that such recall is (A) mandated by any Regulatory Authority, or (B) reasonably requested by RO in writing
if RO has a reasonable basis to conclude that material harm to End Users may occur and GELESIS agrees that a recall is appropriate. GELESIS
shall be responsible for determining whether such recall must be reported to Regulatory Authorities, e.g., under 21 C.F.R. Part 806, and
for all communications with Regulatory Authorities regarding the recall.

 

(c)   
Subject to Section 8.4, any withdrawal or recall with respect to the Product in the Territory required or agreed upon by the Parties
pursuant to this Section 8.3 shall be conducted by GELESIS with reasonable cooperation from RO, regardless of the Party requesting such
withdrawal or recall.

 

8.4.        
Recall and Market Withdrawal Expenses. GELESIS shall bear the expenses of any recall or market withdrawal of a Product;
provided, however, that RO shall bear such expenses if the recall or market withdrawal is due solely to RO’s negligence, willful
misconduct or material breach of its obligations under this Agreement. Such expenses of recall or market withdrawal shall include the
expenses of notification and destruction or return of the recalled or withdrawn Product.

 

		8.5.	Changes.

 

(a)   
Following written notice to RO, GELESIS may amend the Specifications or Product Packaging to the extent required by any applicable
Regulatory Authority or by Applicable Law. In addition, if either Party requests a change to the Specifications or Product Packaging other
than required by any applicable Regulatory Authority or by Applicable Law, it shall provide written notice to the other Party and shall
obtain the other Party’s consent prior to the implementation of such change, which consent may not be unreasonably withheld, conditioned
or delayed. GELESIS shall implement or cause to be implemented any such amendments in a timely manner consistent with Applicable Law and
the obtaining of any necessary Regulatory Approvals.

 

(b)   
Unless otherwise agreed by the Parties in writing, the reasonable expenses incurred in making any changes in the Specifications
or Product Packaging (including the cost of any Inventory rendered unusable due to any such change) shall be borne by (i) GELESIS, if
such change is due to a requirement of an applicable Regulatory Authority or Applicable Law or GELESIS’ request, and (ii) RO, if
such change is due to RO’s request.

 

    17 

     

    

 

(c)   
 Without limiting the foregoing, GELESIS shall provide RO reasonable prior notice of any of the following changes with respect
to the Manufacture of the Product hereunder: (i) any material change relating to the manufacturing facility for any Product; and (ii)
any change that would require a regulatory submission to Regulatory Authorities, where such change relates to, manufacturing facilities,
equipment, process, testing methods, or other procedures used to manufacture the Product.

 

(d)   
GELESIS shall be solely responsible for obtaining any necessary Regulatory Approvals in connection with any change to the Specifications,
Product Packaging, Manufacture of the Product or any other changes related to the Product.

 

ARTICLE 9

INTELLECTUAL
PROPERTY

 

9.1.           
Ownership of Existing Intellectual Property. Subject to the license and other rights granted to RO in Section 2.2, as between
the Parties, GELESIS shall own all right, title, and interest in and to the Product Trademarks, the Company Names, and the other intellectual
property owned or controlled by GELESIS prior to the Effective Date and developed or acquired by GELESIS during the Term independently
of this Agreement (collectively, “GELESIS Intellectual Property”), and RO shall own all right, title, and interest
in and to all intellectual property owned or controlled by RO prior to the Effective Date and developed or acquired by RO during the Term
independently of this Agreement (collectively, “RO Intellectual Property”). All license rights to GELESIS Intellectual
Property not specifically granted under this Agreement are expressly reserved by GELESIS. Any license granted in this Agreement may be
transferred or assigned only in connection with a permitted assignment of this Agreement under Section 14.4.

 

9.2.           
Preservation of Goodwill in Trademarks. GELESIS shall have the right to review and approve RO’s use or display of
the Product Trademarks and Company Names prior to such use or display by RO thereof. GELESIS will provide RO with approval or disapproval
of the proposed use or display within ten (10) Business Days of RO’s submission to GELESIS. In the event that GELESIS fails to respond
within such ten (10) Business Day period, the proposed use or display shall be deemed approved by GELESIS. Without limiting the foregoing,
RO shall, and shall cause its Affiliates to, (a) strictly conform to such guidelines as GELESIS may reasonably provide in writing from
time to time with respect to the manner of use of the Product Trademarks and Company Names and (b) strictly maintain the quality standards
of GELESIS with respect to the goods sold in connection with the Product Trademarks and Company Names.

 

ARTICLE 10

REPRESENTATIONS,
WARRANTIES AND COVENANTS

 

10.1.         
Representations, Warranties and Covenants.    Each Party hereby represents, warrants and covenants to the other Party as
of the Effective Date as follows:

 

(a)    Such
Party (i) is duly organized and in good standing under the laws of the state under which such Party is incorporated, (ii) has the
power and authority and the legal right to enter into this Agreement to which it is a party and to perform its obligations hereunder
and thereunder, and (iii) has taken all necessary action on its part required to authorize the execution and delivery of this
Agreement. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding
obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency
or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability
of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity.

 

    18 

     

    

 

(b)   
All necessary consents, approvals and authorizations of all Regulatory Authorities and other Persons (i) required to be obtained
by such Party in connection with the execution and delivery of this Agreement have been obtained and (ii) required to be obtained by such
Party in connection with the performance of its obligations under this Agreement have been obtained or will be obtained prior to such
performance.

 

(c)   
With respect to such Party, the execution and delivery of this Agreement and the performance of such Party’s obligations
hereunder (i) do not conflict with or violate in any material way any requirement of Applicable Law, (ii) do not conflict with or violate
any provision of the articles of incorporation, bylaws, limited partnership agreement or any other organizational document or similar
instrument of such Party, and (iii) do not conflict with, violate, or breach or constitute a default under, any contractual obligation
or court or administrative order by which such Party is bound.

 

10.2.          Additional Representations, Warranties and Covenants of GELESIS.

 

GELESIS represents, warrants and covenants, as applicable,
to RO that:

 

(a)   
as of the Effective Date, GELESIS is not aware of (i) any pending or threatened product liability actions, suits, proceedings,
claims or investigations against GELESIS (or its predecessors in interest) involving the Product, (ii) any pending or threatened actions,
suits, proceedings, claims or investigations (or has not received any communication) alleging that the Manufacturing, Distribution, or
use of the Product, Product Trademarks or Company Names has infringed, misappropriated, or otherwise violated, or that by conducting the
activities as contemplated in this Agreement either Party would violate, infringe or misappropriate, any of the intellectual property
rights of any other Person, (iii) litigation or investigation(s) initiated by, and warning letters or untitled letters received from,
Regulatory Authorities with respect to the Product, or (iv) any other pending or threatened actions, suits, proceedings, claims, or investigations
that are not covered by the foregoing clauses (i)-(iii) and would reasonably be expected to have (A) a material adverse effect upon, the
operations, business, assets or financial condition of GELESIS taken as a whole, or (B) a material impairment of the ability of
GELESIS to perform its obligations under this Agreement;

 

(b)   
(i) GELESIS and its Affiliates have sufficient legal rights to grant to RO and its Affiliates the licenses and other rights set
forth in this Agreement under the Product Trademarks and Company Names, (ii) GELESIS has not previously licensed, assigned, transferred
or conveyed any of its rights or titles in or interests to the Product Trademarks to a Third Party in a manner that would limit the rights
granted to RO under this Agreement, and (iii) no patent, trademark or other intellectual property rights owned or possessed by Third Parties
would be interfered with, infringed or violated by the Manufacture, Distribution, or use of the Product, or use of the Product Trademarks
and Company Names, in each case, pursuant to the terms hereof;

 

    19 

     

    

 

(c)   
 as of the Effective Date, neither GELESIS nor any of its Affiliates has been debarred or is subject to a debarment proceeding
and neither GELESIS nor any of its Affiliates shall use in any capacity, in connection with the activities to be performed under this
Agreement, any Person who has been debarred pursuant to Section 306 of the Federal Food, Drug, and Cosmetic Act, as amended, or who is
the subject of a conviction described in such section. GELESIS agrees to inform RO in writing immediately if it or any Person who is performing
activities under this Agreement is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to the knowledge of GELESIS, is threatened, relating to the debarment
or conviction described in Section 306 of GELESIS or any Person performing activities under this Agreement;

 

(d)   
the information contained in the Product Packaging complies with Applicable Law as of the Effective Date;

 

(e)   
GELESIS shall comply with all Applicable Laws (including, where applicable, FDA, Federal Trade Commission (“FTC”),
fraud and abuse, wholesale distribution, health, and pharmacy state and federal laws and regulations (including state and federal laws
and regulations related to fee splitting, kickbacks, and physician self-referrals), HIPAA, and state health privacy laws), and will maintain
all Regulatory Approvals with respect to the Product, and proper records in accordance with CGMP and other Applicable Laws in connection
with the Manufacture and sale to RO of the Product; and

 

(f)   
the Product is not reimbursable under any Third Party payer programs as of the Effective Date, and GELESIS will not pursue any
Third Party coverage for the Product during the Exclusive Period; and

 

10.3.          Additional Representations, Warranties and Covenants of RO. RO represents, warrants, and covenants, as applicable, to GELESIS
that:

 

(a)   
RO shall comply with all Applicable Laws (including, where applicable, FDA, FTC, fraud and abuse, wholesale distribution, health,
and pharmacy state and federal laws and regulations (including state and federal laws and regulations related to fee splitting, kickbacks,
and physician self-referrals), HIPAA, and state health privacy laws) in conducting the Distribution of the Product under this Agreement,
and shall maintain proper records in accordance with CGMP and other Applicable Laws in connection with the Distribution of the
Product in the Field in the Territory.

 

(b)   
as of the Effective Date, RO is not aware of any pending or threatened litigation, warning letters, untitled letters, actions,
suits, proceedings, claims or investigations against RO (or its predecessors in interest), which could interfere materially and adversely
with RO’s performance of its obligations and exercise of its rights under this Agreement; and

 

(c)    as
of the Effective Date, neither RO nor any of its Affiliates has been debarred or is subject to a debarment proceeding and neither RO
nor any of its Affiliates shall use in any capacity, in connection with the activities to be performed under this Agreement, any
Person who has been debarred pursuant to Section 306 of the Federal Food, Drug, and Cosmetic Act, as amended, or who is the subject
of a conviction described in such section. RO agrees to inform GELESIS in writing immediately if it or any Person who is performing
activities under this Agreement is debarred or is the subject of a conviction described in Section 306, or if any action, suit,
claim, investigation or legal or administrative proceeding is pending or, to the knowledge of RO, is threatened, relating to the
debarment or conviction described in Section 306 of RO or any Person performing activities under this Agreement.

 

    20 

     

    

 

10.4.         
DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, GELESIS AND RO MAKE NO REPRESENTATIONS
AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND GELESIS AND RO EACH SPECIFICALLY
DISCLAIM ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS
FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY, TITLE, NONINFRINGEMENT OR ENFORCEABILITY OF ANY INTELLECTUAL PROPERTY.

 

ARTICLE 11

CONFIDENTIALITY AND NONDISCLOSURE

 

		11.1.	Confidential Information. During the term of this Agreement and for five

(5) years thereafter, each Party
(the “Receiving Party”) (i) shall hold in strict confidence and shall not publish or otherwise disclose, directly or
indirectly, to any Third Party any Confidential Information of the other Party or its Affiliates (collectively, the “Disclosing
Party”), (ii) except as permitted pursuant to Section 11.2 and Section 11.3, shall not directly or indirectly use Confidential
Information of a Disclosing Party for any purpose other than performance of its obligations or exercise of its rights under this Agreement,
or as otherwise expressly permitted under this Agreement, and (iii) shall use the same level of effort to maintain the confidentiality
of Confidential Information of a Disclosing Party as it uses for its own confidential or proprietary information, but in any event at
least Reasonable Efforts.

 

11.2.         Permitted Disclosure. Each Party may disclose Confidential Information of a Disclosing Party to the extent that such information:

 

(a)   
is already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing
Party, as shown by documentary evidence;

 

(b)   
is part of the public domain at the time of its disclosure by the Disclosing Party; or becomes part of the public domain after
its disclosure by the Disclosing Party other than through any act or omission of the Receiving Party in breach of this Agreement;

 

(c)   
is disclosed to the Receiving Party by a Third Party who had no obligation of non-disclosure with respect to such information;
or

 

(d)   
is independently developed by or for the Receiving Party without reference to such information, as shown by documentary evidence.

 

11.3.         
Disclosure and Use. Each Party may disclose Confidential Information of the other Party to the extent that such disclosure
is:

 

(i)   
 made in response to a valid order of a court of competent jurisdiction or other governmental body of a country or any political
subdivision thereof of competent jurisdiction; provided, however, that the Receiving Party shall, to the extent permitted under Applicable
Law, first provide notice to the Disclosing Party and give the Disclosing Party a reasonable opportunity to quash such order and to obtain
a protective order requiring that the Confidential Information and/or documents containing such Confidential Information that are the
subject of such order be held in confidence by such court or agency, and will reasonably cooperate with the Disclosing Party in seeking
such protection, or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure
order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental
order shall be limited to that information which is legally required to be disclosed in such response to such court or governmental order;

 

    21 

     

    

 

(ii)   
made by the Receiving Party to Third Parties (A) as may be necessary in connection with the Manufacture, Distribution, or otherwise
use of the Product as contemplated by this Agreement, including, customers, or employees; or (B) who is performing diligence in connection
with a transaction with the Receiving Party relating to this Agreement, including a potential investor or an acquirer, in each case ((A)
and (B)), provided that such Third Party shall execute a written confidentiality agreement with the Receiving Party prior to such disclosure,
which agreement shall contain confidentiality terms with respect to such Confidential Information that are no less onerous than those
set forth in this Agreement; or

 

(iii)   
necessary to (A) make a report to Regulatory Authority as required by Applicable Law or permitted herein, or (B) carry out or notify
an affected Person of a product recall, or (C) provide notice under Section 5.4(d) as required to safeguard patient health and safety.

 

11.4.        
Notification.   The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing Party
as the Disclosing Party may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing
Party’s Confidential Information.

 

11.5.        
Remedies. Each Party agrees that the unauthorized use or disclosure of any Confidential Information by the Receiving Party
in violation of this Agreement will cause severe and irreparable damage to the Disclosing Party. In the event of any violation of this
Article 11, the Receiving Party agrees that the Disclosing Party shall be authorized and entitled to seek injunctive relief, whether preliminary
or permanent, as well as any other relief permitted by Applicable Law, without the necessity of proving irreparable injury or actual damages
and without the necessity of having to post a bond.

 

11.6.         
Return of Information. Within thirty (30) days after the expiration or termination of this Agreement, each Party shall return
to the other Party any and all copies of Confidential Information disclosed to it and shall destroy any and all documents, memoranda,
notes, studies and analyses that incorporate or are derived from such information, subject to the Receiving Party retaining a single copy
of such Confidential Information solely for archival purposes.

 

    22 

     

    

 

11.7.         Public
Announcement. The Parties shall coordinate all public announcements and press releases (each a “Public Announcement”)
regarding the relationship of the Parties. Without prejudice to RO’s rights under Article 2, neither Party shall make a Public
Announcement regarding the relationship of the Parties without the prior written approval of the other Party.

 

ARTICLE 12

INDEMNIFICATION

 

12.1.         Indemnification of RO. GELESIS shall defend, indemnify, and hold harmless RO, its Affiliates, and their respective directors,
officers, employees, and agents (collectively, “RO Indemnified Parties”) from and against any and all losses, damages,
liabilities, costs, and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”)
in connection with any and all suits, investigations, claims, or demands of Third Parties (collectively, “Third Party Claims”)
to the extent arising from or occurring as a result of (a) the breach of one or more of GELESIS’ representations or warranties in
this Agreement or the failure by GELESIS to comply with or perform one or more of its covenants in this Agreement, (b) personal injury
or death as a result of use of the Product (or any Third Party Claims in anticipation of, or intended to prevent or forestall any of the
foregoing) (collectively, “Product Liability Claims”), other than the Product Liability Claims described in Section
12.2(b), (c) the Manufacture, supply, handling, storage, shipment, or transport of the Product by or on behalf of GELESIS prior to delivery
to RO pursuant to Section 4.4, or (d) the infringement of Third Parties’ intellectual property rights resulting from the Manufacture
of the Product by GELESIS or from Distribution of the Product supplied to RO in accordance with this Agreement, in each case ((a) through
(d)), except for those Losses arising from or occurring as a result of, directly or indirectly, matters for which RO is obligated to indemnify
GELESIS under Section 12.2, as to which Losses each Party shall indemnify the other to the extent of their respective liability. For the
avoidance of doubt, GELESIS’ indemnification obligations with respect to any Product Liability Claim shall be specifically
covered by subsection (b), and not any other subsections of this Section 12.1.

 

12.2.          Indemnification
of GELESIS. RO shall defend, indemnify, and hold harmless GELESIS, its Affiliates, and their respective directors, officers,
employees, and agents (collectively, “GELESIS Indemnified Parties”) from and against any and all Losses in
connection with any and all Third Party Claims to the extent arising from or occurring as a result of (a) the breach by RO of one or
more of RO’s representations or warranties in this Agreement or the failure by RO to comply with or perform one or more of its
covenants in this Agreement, (b) Product Liability Claims arising from any supply, handling, storage, shipment, or transport by or
on behalf of RO of the Product after delivery by GELESIS to RO pursuant to Section 4.4 that results in the failure of the Product to
conform to the Specifications or the applicable certificate of analysis, (c) the supply, handling, storage, shipment, or transport
of the Product by or on behalf of RO after delivery by GELESIS to RO pursuant to Section 4.4, in each case ((a) through (c)), except
for those Losses arising from or occurring as a result of, directly or indirectly, matters for which GELESIS is obligated to
indemnify RO under Section 12.1, as to which Losses each Party shall indemnify the other to the extent of their respective
liability. For the avoidance of doubt, RO’s indemnification obligations with respect to any Product Liability Claim shall be
specifically covered by subsection (b), and not any other subsections of this Section 12.2.

 

    23 

     

    

 

12.3.            
Indemnification Procedure.

 

(a)   
Notice of Claim; Copies and Cooperation. Each Indemnified Party agrees to give the Indemnifying Party prompt written notice
of any Third Party Claim or the discovery of a fact upon which such Indemnified Party intends to base a request for indemnification under
Section 12.1 or Section 12.2, as the case may be. Each Party shall furnish promptly to the other Parties copies of all papers and official
documents received in respect of any Third Party Claim. The Indemnified Party shall reasonably cooperate as requested by and at the expense
of the Indemnifying Party in the defense of such Third Party Claims.

 

(b)   
Control of Damage Actions. With respect to any Third Party Claim relating solely to the payment of money damages and which
shall not result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely affecting the
Indemnified Party in any manner, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify
the Indemnified Party under this Agreement, the Indemnifying Party shall have the sole right to defend, settle or otherwise dispose of
such Third Party Claim, on such terms as the Indemnifying Party shall deem appropriate.

 

(c)   
Control of Other Actions. With respect to any Third Party Claim other than those addressed in Section 12.3(b), the Indemnifying
Party shall have the sole right to control the defense of such Third Party Claim, provided that the Indemnifying Party shall obtain the
written consent of the Indemnified Party, prior to ceasing to defend, settling or otherwise disposing of such Third Party Claim, which
consent shall not be unreasonably withheld, conditioned or delayed unless as a result thereof, (i) the Indemnified Party would become
responsible for the payment of any money damages or other costs (with respect to which the Indemnifying Party has contested or challenged
or may contest or challenge its obligation to indemnify), (ii) the Indemnified Party would become subject to injunctive or other equitable
relief or any remedy other than the payment of money by the Indemnifying Party or (iii) the Indemnified Party would otherwise be
adversely affected, in which case (i) through (iii) the Indemnified Party may withhold its consent in its sole discretion.

 

12.4.         
Insurance. GELESIS shall maintain workers’ compensation coverage sufficient to meet the statutory requirements of every
state in which GELESIS’ personnel are engaged in activities contemplated under this Agreement. In addition, GELESIS agrees to obtain
and maintain at all times while this Agreement remains in effect: (a) Commercial General Liability Insurance with a minimum limit per
occurrence of $1,000,000 and a minimum aggregate limit of $2,000,000; (b) Product Liability Insurance with a combined single limit
of at least $7,000,000 per occurrence and in the aggregate; and (c) Excess or Umbrella Liability with a minimum limit of $5,000,000 per
occurrence over the insurance coverage described above. Such insurance shall protect GELESIS from claims for property damage and personal
injury (including bodily injury and death), as applicable. All insurance shall be primary and not contributory with regard to any other
insurance available to RO or its Affiliates. All insurance shall be underwritten by companies having a minimum AM Best rating of A-,
XV. Certificates of insurance (or copies of policies, if required by RO) shall be furnished to RO, and such policies shall (i) other
than with respect to workers’ compensation coverage, include RO, its Affiliates, and each of their respective owners, officers,
directors, agents, contractors and employees as additional insureds and, (ii) include a waiver of subrogation in favor of RO and its
Affiliates, to the fullest extent permitted by Applicable Law.

 

    24 

     

    

 

 

12.5.       
Limitation on Damages. EXCEPT AS ARISING FROM A BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 11 OR PURSUANT TO THIS
ARTICLE 12 (INDEMNIFICATION), NEITHER RO NOR GELESIS SHALL BE LIABLE TO THE OTHER FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL
DAMAGES, INCLUDING LOSS OF BUSINESS, GOODWILL, REVENUE OR PROFITS, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY
OR OTHERWISE, WHETHER ARISING OUT OF THE MANUFACTURE, USE OR SALE OF THE LICENSED PRODUCT BY THE OTHER PARTY OR OTHERWISE.

 

ARTICLE 13

TERM AND TERMINATION

 

13.1.       
Term. The term of this Agreement shall commence upon the Effective Date and shall continue in effect until terminated pursuant
to Section 13.2 (the “Term”).

 

		13.2.	Termination.

 

(a)       
Termination for Material Breach. If either Party is in material breach in the performance of any of its obligations under
this Agreement (the “Breaching Party”), the other Party (the “Complaining Party”) may terminate
this Agreement upon thirty (30) days’ prior written notice (the “Notice Period”) to the Breaching Party, specifying
the breach and its claim of right to terminate, provided that the termination shall not become effective at the end of the Notice Period
if the Breaching Party cures the breach during the Notice Period.

 

(b)       
Termination Upon Insolvency. Either Party may terminate this Agreement if, at any time, the other Party shall file in any
court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets, or if
such other Party proposes a written agreement of composition or extension of its debts, or if such other Party shall be served with an
involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days
after the filing thereof, or if such other Party shall propose or be a party to any dissolution or liquidation, or if such other Party
shall make an assignment for the benefit of its creditors.

 

(c)       
Mutual Agreement. This Agreement may be terminated upon mutual agreement between the Parties.

 

(d)       
[***].

 

(e)       
Termination for Prolonged Force Majeure. This Agreement may be terminated for prolonged Force Majeure (ninety (90) days
or more) pursuant to and in accordance with Section 14.1.

 

		13.3.	Effect of Termination.

 

(a)       
Supply of Prior Orders. Upon termination of this Agreement for any reason, GELESIS shall not have any further obligation
to supply any Product to RO, provided that GELESIS shall Manufacture (or cause the Contract Manufacturer to Manufacture) and deliver
(or cause the Contract Manufacturer to deliver) in accordance with the terms of this Agreement all quantities of the Product set forth
in any Purchase Order submitted by RO prior to the date of termination, unless otherwise agreed in writing by the Parties. The delivery
terms, payment terms, and any other applicable terms and conditions of this Agreement shall apply to such Product.

 

    25 

     

    

 

(b)       
Inventory. Upon termination of this Agreement for any reason, RO shall have the right to sell its inventory of the Product
in the Field in the Territory subject to Section 6.2.

 

(c)       
Licenses. Upon termination of this Agreement for any reason, all rights and licenses granted by GELESIS to RO under Section
2.2 shall terminate, provided that (i) RO shall have the right to use the Product Trademarks and Company Names after termination for
the purposes of selling off its inventory of Product; and (ii) RO and its Affiliates shall have no obligation to remove content or materials
incorporating the Product Trademarks or Company Names in connection with Distribution of the Product which were permeated on any website
or platform (e.g., Instagram) or otherwise disseminated on any website or platform in accordance with the terms and conditions of this
Agreement prior to the termination.

 

(d)       
Intentionally Omitted.

 

(e)       
Pharmacy Transfer Coordination. Upon expiration or termination of this Agreement, to the extent permitted by Applicable
Law, RO will coordinate the transfer of Product prescriptions to a pharmacy of the patient’s choice that carries the Product to
ensure continuity of care to patients. GELESIS will work in good faith with RO, as needed, to coordinate such transfers.

 

13.4.       
Accrued Rights; Surviving Obligations.

 

(a)       
The termination of this Agreement for any reason shall be without prejudice to any rights that have accrued to the benefit of
a Party prior to such termination. Such termination shall not relieve a Party from obligations that are expressly indicated to survive
the termination of this Agreement. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the
provisions hereof shall not limit remedies which may otherwise be available to a Party in law or equity.

 

(b)       
Articles 9, 11, 12 and 14 and Sections 5.1, 5.3, 10.4, 13.3, and 13.4 of this Agreement shall survive termination of this Agreement.

 

ARTICLE 14

MISCELLANEOUS

 

14.1.       
Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under
or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement, when such failure or delay is
caused by or results from causes beyond the reasonable control of the non-performing Party, including fires, floods, embargoes, shortages,
war, acts of war (whether war be declared or not), insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances,
acts of God (collectively, “Force Majeure”). The non-performing Party shall notify the other Party of such
force majeure within ten (10) days after such occurrence by giving written notice to the other Party stating the nature of the event,
its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater
scope and no longer duration than is necessary and the non-performing Party shall use Reasonable Efforts to remedy its inability to perform;
provided, however, that in the event the suspension of performance continues for thirty (30) days after the date such event of Force
Majeure commences, the Parties shall meet to discuss in good faith how to proceed in order to carry out the intent of this Agreement;
provided further, that in the event the suspension of performance continues for ninety (90) days after the date such event of Force Majeure
commences, the Party who, absent this Section 14.1, would have a claim for breach may terminate this Agreement immediately upon written
notice to the other Party. For purposes of this Agreement, an event of Force Majeure shall not include a failure to commit or secure
sufficient resources or capacity, financial or otherwise, to the performance of obligations under this Agreement, or general market or
economic conditions.

 

    26 

     

    

 

14.2.       
Further Assurance. Each Party shall, and shall cause its Affiliates to, cooperate with and provide assistance to the other
Party in support of such other Party’s exercising its right or performing its obligations under this Agreement. Without limiting
the foregoing, GELESIS agrees that, to the extent available and permitted under Applicable Law, it will, and will cause its Affiliates
to provide to RO such additional information or documentation relating to the Product as may be reasonably requested by RO, and that
is necessary or reasonably useful to facilitate RO’s Distribution of the Product, at no additional charge to RO, and each Party
shall, and shall cause its Affiliates to, otherwise duly execute and deliver, or cause to be duly executed and delivered, such further
instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents,
and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more
effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this
Agreement.

 

14.3.       
Notice. Unless otherwise expressly provided herein, all notices or other communications which are required or permitted
hereunder shall be in writing and delivered personally, sent by email of a PDF attachment, by nationally-recognized overnight courier
or by registered or certified mail, postage prepaid, return receipt requested, in each case, to the addresses set forth below:

 

    27 

     

    

 

	if to GELESIS: 	Gelesis Inc.
	 	501 Boylston Street, Suite 6102
	 	Boston, MA 02116
	 	Attention:   David Pass, COO and Head of Commercial
	 	[***]
	 	 
	with a copy to: 	Goodwin Procter LLP
	 	100 Northern Ave.
	 	Boston, MA 02210
	 	Attention: Jim Barrett
	 	Email: jbarrett@goodwinlaw.com
	 	 
	if to RO:	Roman Health Pharmacy LLC
	 	900 Broadway, Suite 706
	 	New York, NY 10003
	 	Attention: Zachariah Reitano
	 	[***]
	 	 
	with a copy to: 	Roman Health Ventures Inc.
	 	116 W. 23rd Street, 4th Floor
	 	New York, NY 10011
	 	Attn: General Counsel
	 	[***]
	 	 
	 	and
	 	 
	 	Covington & Burling LLP
	 	One CityCenter
	 	850 Tenth Street, NW
	 	Washington, DC 20001-495
	 	Attention: Van Ellis
	 	Email: VEllis@cov.com

 

or to such other address as the
Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such communication shall
be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile or email on a Business Day, (b) on the
Business Day after dispatch, if sent by nationally-recognized overnight courier, and (c) on the third Business Day following the date
of mailing, if sent by mail.

 

14.4.       
Assignment. Neither Party shall be entitled to assign its rights or delegate its obligations under this Agreement without
the express written consent of the other Party, except that (a) each Party may, without such consent of the other Party, assign its rights
or delegate its duties under this Agreement to an Affiliate that is a directly or indirectly wholly-owned subsidiary, provided, however,
that the assigning Party shall remain primarily (and not secondarily or derivatively) liable for the full and timely performance by such
Affiliate of all its obligations under this Agreement, or (b) either Party may, without such consent, assign its rights and delegate
its duties under this Agreement, whether by contract or operation of law, to a Third Party Acquirer in the event of a Change of Control
of such Party. Any permitted successor or assignee of rights or obligations under this Agreement shall, in a writing delivered to the
other Party, expressly assume performance of such rights or obligations. All validly assigned and delegated rights and obligations of
the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted
assigns of the respective Parties. Any assignment not in accordance with this Section 14.4 shall be void.

 

    28 

     

    

 

14.5.       
Governing Law. This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of
Delaware excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this
Agreement to the substantive law of another jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods
is expressly disclaimed by the Parties with respect to this Agreement and the transactions contemplated hereby.

 

14.6.       
Dispute Resolution. Except as provided in Sections 4.6, 5.4, 11.5 and 14.6(b), if a dispute arises between the Parties
in connection with this Agreement or any document or instrument delivered in connection herewith, including an alleged breach of any
representation, warranty or covenant herein or therein, or a disagreement regarding the interpretation of any provision hereof
or thereof (a “Dispute”), the Parties shall resolve such Dispute in accordance with this Section 14.6:

 

(a)       
Any Dispute shall be referred to and finally resolved by arbitration administered by the International Chamber of Commerce (the
 “ICC”) in accordance with the then- prevailing ICC Rules of Arbitration. The number of arbitrators shall be three
(3). The legal place of arbitration shall be New York, New York. The language of the arbitration shall be English.

 

(i)       
The Party commencing the arbitration shall designate an arbitrator in its notice of arbitration. The other Party shall designate
an arbitrator within thirty (30) days from the receipt of the notice of arbitration. The third arbitrator shall be chosen promptly by
mutual agreement of the two party-designated arbitrators, but in no event later than thirty (30) days after the date on which the second
arbitrator is confirmed or appointed.

 

(ii)       
Any award issued by the arbitrators (including an interim, interlocutory, partial, or final award) shall be issued, with all reasonable
expediency, in writing and shall include a statement of decision describing the essential findings and conclusions on which the award
is based, including, where applicable, the calculation of any damages awarded. The decision or award rendered by the arbitrators shall
be final and non-appealable, and judgment may be entered upon it in accordance with applicable law in any court of competent jurisdiction.
The arbitrators shall be authorized to award compensatory damages, but shall not be authorized to reform, modify, or materially change
this Agreement or any other agreements contemplated hereunder. Each Party shall bear its own counsel fees, costs, and disbursements arising
out of the arbitration described in this Section 14.6(a) and shall pay an equal share of the fees and expenses of the arbitrators and
of the ICC.

 

(b)       
Nothing in this Agreement, including this Section 14.6, shall preclude either Party from seeking interim or provisional relief,
including a temporary restraining order, preliminary injunction or other interim equitable relief concerning a dispute with the other
Party, either prior to or during the dispute resolution procedures set forth in this Section 14.6, if necessary to protect the interests
of such Party. This Section 14.6(b) shall be specifically enforceable.

 

    29 

     

    

 

14.7.       
Consent to Jurisdiction. Each Party, for the purpose of enforcing an award under Section 14.6(a) or for seeking injunctive
or other equitable relief as permitted by Sections 11.5 and 14.6(b) or elsewhere hereunder, (a) irrevocably submits to the exclusive
jurisdiction of the United States District Courts located in the State of Delaware (the “Court”), and (b) agrees not
to raise any objection at any time to the laying or maintaining of the venue of any action, suit or proceeding in the Court, irrevocably
waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives
the right to object, with respect to such action, suit or other proceeding, that such Court does not have any jurisdiction over such
Party. Each Party further agrees that service or any process, summons, notice or document by U.S. registered mail to such Party’s
notice address provided for in this Agreement shall be effective service of process for any action, suit or proceeding in the Court with
respect to any matters to which it has submitted to jurisdiction in accordance with this Section 14.7.

 

14.8.       
Status of the Parties. Except as set forth expressly in this Agreement, nothing in this Agreement shall give either Party
the right to enter into any agreements or take action on behalf of the other Party, nor shall it represent to any Person that it has
any such right or authority under this Agreement. It is expressly agreed that RO and GELESIS shall be independent contractors and that
the relationship between RO and GELESIS shall not constitute a partnership, joint venture, or agency.

 

14.9.       
No Third Party Beneficiaries. Except as set forth in Sections 12.1 and as to those Third Parties expressly referred to therein,
the agreements, covenants, and representations contained herein are for the benefit of the Parties only and are not for the benefit of
any Third Party.

 

14.10.       
Amendment. This Agreement may not be amended in any respect whatsoever except according to its explicit terms or by a further
written agreement executed by each of the Parties.

 

14.11.       
Waiver. A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or
to exercise any right or remedy, does not constitute a waiver of such provision, right or remedy, nor does such failure in one or more
instances constitute a continuing waiver or a waiver in other instances by such Party. The exercise of any right or remedy does not constitute
an election or prevent the exercise of any or all rights or remedies, all rights and remedies being cumulative.

 

14.12.       
Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future
law, and if the rights or obligations of any Party under this Agreement will not be materially and adversely affected thereby, (a) such
provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision
had never compromised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not
be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid
or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as
similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein.
To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof
prohibited or unenforceable in any respect.

 

    30 

     

    

 

14.13.       
Entire Agreement. This Agreement, including the Schedules, which are attached hereto and incorporated herein by reference,
constitutes, on and as of the Effective Date, the entire agreement of the Parties with respect to the subject matter hereof, and all
prior or contemporaneous understandings or agreements, whether written or oral, between the Parties with respect to such subject matter,
including without limitation the confidentiality agreement between the Parties dated as of March 12, 2019 are hereby superseded in their
entireties. This Agreement shall not be amended in any respect whatsoever except by a further agreement, in writing, fully executed
by each of the Parties.

 

14.14.       
Construction. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural
includes the singular, and the word “or” is used in the inclusive sense (and/or). The term “including” or its
variations as used herein does not limit the generality of any description preceding such term. The language of this Agreement shall
be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party.
Unless otherwise specified or where the context otherwise requires, (a) references in this Agreement to any clause, paragraph, or schedule
are references to such clause, paragraph, or schedule of this Agreement, and references to this Agreement are references to this Agreement
and all schedules hereto; (b) “hereof,” “hereto,” “hereby,” “herein” and “hereunder”
and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this
Agreement; (c) references to a Person are also to its permitted successors and assigns; (d) references to a Law include any amendment
or modification to such Law and any rules, regulations or legally binding guidelines issued thereunder, in each case, as in effect at
the relevant time of reference thereto; (e) references to any agreement, instrument or other document in this Agreement refer to such
agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time,
as so amended, replaced or supplemented and in effect at the relevant time of reference thereto; (f) “extent” in the phrase
 “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if”;
(g) references to monetary amounts are denominated in United States Dollars (“Dollar” or “$”); and (h) references
to days (excluding Business Days), weeks, months, quarter, or year shall be deemed references to calendar days, weeks, months, quarter,
or year.

 

14.15.       
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original,
and all of which, taken together, shall constitute one and the same instrument. This Agreement, to the extent signed and delivered by
electronic means, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have
the same binding legal effect as if it were the original signed version thereof delivered in person.

 

[Signature Page Follows]

 

    31 

     

    

 

CONFIDENTIAL

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the Effective Date.

 

	GELESIS INC.	 	ROMAN
                                            HEALTH PHARMACY LLC
	 	 	 
	By:	/s/ David Pass	 	By:	/s/ Geroge Koveos
	Name: David Pass	 	Name: George Koveos
	Title: COO/CCO	 	Title: COO

 

    32 

     

    

 

CONFIDENTIAL

 

Schedule A

 

Product Specifications

 

		·	PLENITYTM
                                            monthly box: approx.. 162.5 mm x 139.5 mm x 139.5 mm, 2 mm rigid gray board, 4C matte, PP
                                            lamination, wrap liner paper is 157G C2S, CIE whiteness 113.

 

		·	Shipper:
                                            white, printed 2C flexo, 32#, approx.. 18” x 11 1⁄4” x 13”

 

		·	The
                                            above product specifications may subject to change over time.

 

    33 

     

    

 

CONFIDENTIAL

 

Schedule B

 

Contract Manufacturer

 

Packaging – Centerpiece Holdings LLC

440 Stevens Ave, Ste 200

Solana Beach, CA 92075

 

    34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]